Actemra
Payments companies reported to CMS as associated with Actemra. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Actemra, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Actemra
These are the largest totals companies reported as associated with Actemra. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| John Cush | Dallas, TX | Rheumatology | $28,000.00 |
| Aaron Broadwell | Shreveport, LA | Rheumatology | $8,307.10 |
| Grace Wright | New York, NY | Rheumatology | $5,932.59 |
| Orrin Troum | Santa Monica, CA | Rheumatology | $5,847.47 |
| Alvin Wells | Destin, FL | Rheumatology | $5,834.07 |
| Cesar Briceno | Philadelphia, PA | Ophthalmology | $5,250.00 |
| Peter Merkel | Radnor, PA | Rheumatology | $3,639.70 |
| Atif Collins | Fresno, CA | Ophthalmic Plastic and Reconstructive Surgery | $2,875.00 |
| John Leonard | New York, NY | Hematology & Oncology | $2,640.00 |
| Matthew Matasar | New York, NY | Medical Oncology | $1,980.00 |
Prescribed Actemra?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.